BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: HLXB) is a blank check company incorporated to pursue a business combination in the oncology and broader life sciences sector. The company filed a Form 10-Q with the Securities and Exchange Commission on May 15, 2024, reflecting its financial position as an active SPAC in the search phase during that reporting period. Focused on healthcare therapeutics, HLXB is part of the cohort of sector-specific SPACs that continued pursuing acquisition targets through the extended post-peak SPAC market cycle. For full filing history, sponsor details, pipeline status, and real-time deal data on HLXB and the broader SPAC universe, sign up for complete access on SpacDesk.